Immunomedics Inc
IMMU
IMMU was delisted on the 22nd of October, 2020.
150 hedge funds and large institutions have $1.62B invested in Immunomedics Inc in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 55 increasing their positions, 43 reducing their positions, and 13 closing their positions.
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
112% more capital invested
Capital invested by funds: $766M → $1.62B (+$856M)
88% more call options, than puts
Call options by funds: $86.8M | Put options by funds: $46.1M
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
28% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 43
15% more funds holding
Funds holding: 130 → 150 (+20)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$51.2M |
| 2 |
O
OrbiMed
New York
|
+$50.5M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$42.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$28.5M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$27.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$37.3M |
| 2 |
Millennium Management
New York
|
-$13.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.27M |
| 4 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.35M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$5.12M |
IMMU Hedge Fund Activity: Q3 2017 in Review
150 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q3 2017, worth a combined $1.62B — up 112% from $766M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new IMMU positions and 13 closed out — a net gain of 22 holders — while 55 added to existing stakes and 43 trimmed.
The largest buyer was Acuta Capital Partners, adding an estimated $51.2M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $37.3M sold.
- 150 institutional investors held Immunomedics Inc (IMMU) as of Q3 2017, up from 130 in Q2 2017.
- Funds reported $1.62B of Immunomedics Inc stock for Q3 2017, up 112% quarter-over-quarter.
- 35 funds opened new Immunomedics Inc positions in Q3 2017 and 13 closed out, a net change of +22 holders.
- The largest Immunomedics Inc buyer in Q3 2017 was Acuta Capital Partners, an estimated $51.2M added.
- The largest Immunomedics Inc seller in Q3 2017 was Farallon Capital Management, an estimated $37.3M sold.
Based on aggregated 13F filings for Q3 2017.